Bionomics files key U.S. patents relating to cancer drug target BNO69

October 12, 2017

The role of BNO69 as a target for inhibiting angiogenesis (blood vessel formation) was published late last year in the prestigious scientific journal Proceedings of the National Academy of Sciences USA (PNAS) and more recently in the scientific journal Physiological Genomics. Recent clinical successes with drugs which inhibit angiogenesis, a key factor in the growth of solid cancers, have intensified the interest of pharmaceutical companies in this area.

More recent findings indicate that BNO69 and molecules that silence its expression may have therapeutic utility in directly targeting cancer cells. Cell-based assays demonstrated that BNO69 silencing molecules curtail the tumorigenic behaviour exhibited by a number of tumour cell types, including, breast and colon cancer. Previously reported animal studies have shown that molecules which silence BNO69 have a profound effect on tumour growth and that BNO69 is potentially an effective drug target for treating breast cancer. In those studies, breast cancer cells that were treated with BNO69 gene-silencing molecules showed a significantly reduced capacity in forming solid tumours in mice. Solid tumours arising from cells treated with BNO69 silencing molecules were over 75% smaller compared to tumours arising from untreated cells. Bionomics has confirmed this data in repeat studies with observed tumour size reductions as high as 94%.


Age and income also appeared to be factors predicting poor understanding of insurance coverage. Women 65 years and older and women earning less than $20,000 per year were found to be significantly more likely to misunderstand their insurance coverage of screening mammography.

The researchers say that screening utilization campaigns should not only push for greater insurance coverage, but also educate women about their own insurance coverage.

The authors conclude that "these results suggest that improving women's knowledge about the actual out-of-pocket costs and insurance coverage for screening mammograms may reduce the overall impact of cost as a barrier."

The study will appear in the June 15, 2005 issue of CANCER.